XOMA Royalty Corp is an SEC registrant, filing under CIK 0000791908, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
Footnote F7 (price): The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
Footnote F1 (shares): Includes 513 shares acquired under the ESPP Plan on May 31, 2026.
Footnote F2 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F3 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F4 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F4 (price, shares): Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of… Full note on SEC EDGAR
Footnote F5 (price, shares): Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F4 (price, shares): Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F4 (price, shares): Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of… Full note on SEC EDGAR
Footnote F1 (shares): Includes 804 shares acquired under the ESPP Plan on May 31, 2026.
Footnote F2 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F3 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F4 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F5 (price, shares): Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of… Full note on SEC EDGAR
Footnote F6 (price, shares): Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F1 (price, shares): Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals… Full note on SEC EDGAR
Footnote F2 (price, shares): At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement… Full note on SEC EDGAR
Footnote F3 (price, shares): At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax… Full note on SEC EDGAR
Footnote F1 (shares): Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued… Full note on SEC EDGAR
Footnote F1 (shares): Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued… Full note on SEC EDGAR
Footnote F1 (shares): Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued… Full note on SEC EDGAR
Footnote F1 (shares): Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued… Full note on SEC EDGAR
Footnote F1 (shares): Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued… Full note on SEC EDGAR
Footnote F1 (shares): Consists of 3,586 restricted stock units ("RSUs"). Each RSU represents the right to receive, at settlement, one share of common stock of the Company and will vest in equal parts on a monthly basis, for 12 months from the date of grant, subject to the reporting person's continued… Full note on SEC EDGAR
Footnote F1 (shares): Represents a grant of restricted stock units payable solely in common stock that will vest as to 25% on each of the first four anniversaries of March 11, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Footnote F1 (shares): Represents a grant of restricted stock units ("RSUs") payable solely in common stock that will vest in full on March 11, 2031, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Footnote F2 (shares): Represents a grant of RSUs payable solely in common stock that will vest as to 25% on each of the first four anniversaries of March 11, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Footnote F1 (shares): Represents a grant of restricted stock units payable solely in common stock that will vest as to 25% on each of the first four anniversaries of January 12, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Footnote F1 (shares): Represents a grant of restricted stock units payable solely in common stock that will vest as to 25% on each of the first four anniversaries of March 11, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date.
XOMA Royalty Corp (XOMA) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-16. The full record for XOMA runs to 42 Form 4 filings, the earliest from 2024-11-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying XOMA stock?
No insider purchases of XOMA were filed in the last 90 days. 6 purchases are on record for this company.
How many insiders are selling XOMA stock?
No insider sales of XOMA were filed in the last 90 days. 7 sales are on record for this company.
Where can I see XOMA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects XOMA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
